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A myotrophic lateral sclerosis (ALS) is a prototypical neurodegenerative disease that is characterized by the progressive degeneration of motor neurons in the brain and spinal cord. The condition was first described by the neurologist Jean-Martin Charcot, and its name reflects both the degeneration of corticospinal motor neurons, the descending axons of which in the lateral spinal cord seem scarred (lateral sclerosis), and the demise of spinal motor neurons, with secondary denervation and muscle wasting (amyotrophy). Corticospinal neurons make direct or indirect connections with spinal motor neurons, which innervate skeletal muscles and trigger their contraction (Fig. 1a) . This Review summarizes the clinical and pathological features of ALS and describes how discoveries in ALS genetics have illuminated important themes in the molecular pathophysiology of the disease.
ALS is known as Lou Gehrig's disease in the United States and as motor neuron disease in the United Kingdom. Although onset of the disease occurs commonly in mid-adulthood (at a mean age of 55 years), ALS might begin as early as in the first or second decade of life or could even emerge in later life. Similar to most neurodegenerative diseases, it starts focally and spreads: symptoms that start as subtle cramping or weakness in the limbs or bulbar muscles progress to the paralysis of almost all skeletal muscles. Some subsets of motor neurons, including those that innervate the extraocular muscles or sphincters, are spared until late in the progression of the disease. However, ALS is invariably fatal. Death occurs typically 3-5 years after diagnosis, although some forms of the disease demonstrate protracted survival.
ALS is an orphan disease that is diagnosed in 1-2 individuals per 100,000 each year in most countries; the prevalence of ALS is about 5 cases per 100,000 people, which reflects the rapid lethality of the disease 1 . In the United States and United Kingdom, ALS causes more than 1 in 500 deaths in adults, a statistic that suggests that more than 15 million people who are alive at present will succumb to the disease.
The clinical manifestations of ALS
Considerable heterogeneity exists in the general rubric of ALS. Clinical subsets of the disease are distinguished by the involvement of different sets of motor neurons or different regions of the body. Depending on the location of the main pathology, those affected might develop weakness with flaccidity and atrophy of the limbs (known as progressive muscular atrophy, which mainly affects spinal neurons or lower motor neurons), prominent hyperreflexia and spasticity with increased limb tone but little muscle atrophy (known as primary lateral sclerosis, which affects corticospinal motor neurons with limited involvement of spinal motor neurons), tongue atrophy with thickness of speech and difficulty swallowing (known as bulbar ALS, which affects brainstem motor neurons that serve the muscles of tongue movement, chewing, swallowing and articulation) or slow and highly dysfunctional speech and swallowing in the absence of tongue atrophy, often accompanied by the accentuation of emotional reflexes (known as pseudobulbar palsy, which affects cortical frontobulbar motor neurons). Importantly, ALS shares clinical and pathological features with several other adult-onset degenerative disorders, including, most frequently, frontotemporal dementia (FTD), which could constitute a clinical spectrum (Box 1).
Genetic contributions to ALS
About 10% of ALS cases are transmitted in families, almost always as a dominant trait and frequently with high penetrance. The first genetic mutations found to cause ALS, reported in 1993, affected the gene SOD1 (ref. 2 ) and more than 50 further potential ALS genes have been published since, although validating the causality of specific variants remains a challenge. By applying rigorous criteria, a list of genes with mutations that are implicated unequivocally in the pathogenesis of ALS can be generated (Table 1) . These genes can be grouped into several loose categories: genes that alter proteostasis and protein quality control; genes that perturb aspects of RNA stability, function and metabolism; and genes that disturb cytoskeletal dynamics in the motor neuron axon and distal terminal. The mutations involved are mostly missense substitutions, although the genetic lesion in C9orf72 is an enormous expansion of an intronic hexanucleotide repeat.
Although sporadic ALS should refer strictly to disease that presents without a family history of ALS, this term is sometimes mistakenly used to refer to ALS that occurs without a genetic basis. Technological advances that facilitate broad DNA sequencing in people with sporadic ALS have revealed that genetic variants in established ALS genes are not infrequent. For example, it is now evident that 1-3% of sporadic cases of ALS are caused by missense mutations in SOD1 (ref.
3) and another 5% or more are caused by intronic expansions in C9orf72 (ref. 4) . Pathogenic mutations in other ALS genes, including TARDBP, FUS, HNRNPA1, SQSTM1, VCP, OPTN and PFN1, have also been identified Amyotrophic lateral sclerosis (ALS) is a progressive and uniformly fatal neurodegenerative disease. A plethora of genetic factors have been identified that drive the degeneration of motor neurons in ALS, increase susceptibility to the disease or influence the rate of its progression. Emerging themes include dysfunction in RNA metabolism and protein homeostasis, with specific defects in nucleocytoplasmic trafficking, the induction of stress at the endoplasmic reticulum and impaired dynamics of ribonucleoprotein bodies such as RNA granules that assemble through liquid-liquid phase separation. Extraordinary progress in understanding the biology of ALS provides new reasons for optimism that meaningful therapies will be identified.
in people with sporadic ALS, although they are rare.
Genetic variants that enhance susceptibility to ALS or that modify the clinical phenotype are of immense interest, even if the variants themselves do not cause ALS. For example, large expansions of repeats of the trinucleotide CAG in the coding sequence of the gene ATXN2 cause spinocerebellar ataxia type 2, in which motor weakness is sometimes an early presentation. It is striking therefore that modest expansions to 27-33 CAG repeats in ATXN2 increase the risk of developing ALS 5 . By contrast, variants that reduce expression of the axonal guidance gene EPHA4 improve the overall survival of people with ALS 6 .
The pathology of ALS
Autopsies of people with ALS reveal the degeneration of motor neurons in the motor cortex of the brain, in the brainstem motor nuclei and in the anterior horns of the spinal cord. As spinal motor neurons degenerate, their target muscles become atrophied. Degeneration of the spinal processes of corticospinal neurons results in scarring in the lateral tracts of the spinal cord. As ALS progresses further, affected spinal motor neurons shrink and accumulate rounded or threadlike deposits of aggregated proteins that are referred to collectively as inclusions (Fig. 1b) . The cytoplasmic inclusions in ALS often become ubiquitinated; an initial target for ubiquitination is TAR DNA-binding protein , encoded by the gene TARDBP, which forms the main component of ubiquitinated inclusions in most cases of ALS 7 .
Other pathological features are associated with specific genes. For example, cases of ALS caused by a large expansion of a hexanucleotide repeat in C9orf72 show intranuclear RNA foci 8 , as well as neuronal cytoplasmic inclusions, predominantly in the cerebellum and hippocampus, that contain the protein sequestosome-1 (also known as ubiquitin-binding protein p62 and encoded by the gene SQSTM1) but are distinct from TDP-43 inclusions that are also present in such individuals (ref. 9). Cases of ALS caused by mutations in the genes SOD1 or FUS are pathologically distinct because they exhibit inclusions of abnormal SOD1 or FUS proteins, respectively, rather than those of TDP-43. In addition to these findings in motor neurons, there is also abundant evidence of relevant pathology in non-neural cell types (for example, insidious astrogliosis and microgliosis). It is probable that both of these forms of non-cellautonomous cellular reactivity influence adversely the progression of ALS.
Pathogenic mechanisms of ALS
The molecular era of discovery in ALS began with the identification of dominant mutations in the gene SOD1, which encodes an abundant, ubiquitously expressed cytoplasmic enzyme called Cu-Zn superoxide dismutase 2 . An important antioxidant, the normal function of SOD1 is to catalyse the conversion of highly reactive superoxide (most frequently produced by errors in mitochondria) to hydrogen peroxide or oxygen.
The expression of mutant SOD1 in mice demonstrated that the degeneration of motor neurons is driven by one or more acquired toxicities of the mutant protein 10, 11 and is independent of dismutase activity 12 . The more than 170 ALS-causing mutations that have now been identified (http://alsod.iop.kcl.ac.uk/) lie in almost every region of the 153-aminoacid SOD1 polypeptide. Moreover, although many variants retain partial or full dismutase activity, there is no correlation between a reduction in activity and the age of disease onset or the speed of disease progression 13 . These findings led to the consensus that disease arises from one or more toxic properties of the many SOD1 mutants rather than from reduced dismutase activity.
A sobering reality, however, is that in the 23 years since the discovery of mutations in SOD1, no consensus on the main toxicity of mutant SOD1 has emerged. Instead, a plethora of toxic mechanisms that mediate the degeneration and death of motor neurons have been proposed (Fig. 2) . A prominent finding is that a proportion of each ALS-causing SOD1 mutant fails to fold properly, which implicates the accumulation of misfolded SOD1 as a possible contributor to toxicity in ALS. Misfolded SOD1 forms ubiquitinated cytoplasmic inclusions that can occur early in ALS and that escalate as the disease progresses 14 . The accrual of ubiquitinated SOD1 aggregates in people with SOD1 mutations is paralleled by the accrual of ubiquitinated TDP-43 aggregates in people with TARDBP mutations (as well as in most people with sporadic ALS), which highlights a correlation between protein aggregation and ALS. However, as has been demonstrated for other neurodegenerative diseases, large aggregates of disease-causing mutant SOD1 are not sufficient to drive disease because their elimination fails to affect any aspect of the fatal disease that develops in mice expressing ALS-linked mutants of SOD1 (ref. 15 ).
Non-cell-autonomous toxicity
Similar to the genes implicated in other main neurodegenerative diseases, all genes in which ALS-causing mutations occur are expressed in many cell types. Indeed, it is now clear that ALS arises, in part, through noncell-autonomous mechanisms. This means that the disease is the result of a combination of damage from mutant SOD1 in both motor neurons and their glial partners, rather than from damage to neurons alone.
For mutant SOD1, this concept is underscored by studies in mice 
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revealing that high levels of mutant SOD1 expression in all motor neurons is not sufficient to cause early onset disease 16 . Conversely, a reduction in the synthesis of mutant SOD1 in motor neurons does not slow the rate of progression after the onset of disease, even when applied before symptoms occur [17] [18] [19] . Therefore, ALS is a disease not just of the motor neuron but also of the motor system, which is comprised of motor neurons and intimately associated cells of several types.
The crucial role of glia in ALS
The importance of glial cells in the degeneration and death of motor neurons emerged from studies in which the synthesis of mutant SOD1 was silenced in microglia, astrocytes or oligodendrocyte precursor cells. Microglia, which are the innate immune cells of the nervous system, become activated in all types of ALS (Fig. 2b) . The synthesis of mutant SOD1 by microglia is an important determinant of rapid disease progression, as determined by selectively silencing the mutant gene SOD1 in microglia 19 or by using cell grafts to replace microglia expressing mutant SOD1 with normal microglia 20 . Consistent with these findings, inhibition of the transcription factor NF-κB suppresses this neuroinflammatory component of microglial toxicity in co-cultured motor neurons 21 . A further mechanism of damage that results from mutant SOD1 produced by microglia is counterintuitive: stimulation of the excessive extracellular production of superoxide 22 . Misfolded mutant SOD1 can associate with the small GTPase RAC1, which controls the activation of NADPH oxidase, a complex that produces superoxide (Fig. 2b) . So, instead of its normal function of removing intracellular superoxide, mutant SOD1 could drive microglia to produce high levels of extracellular superoxide.
Disturbances in microglial function have also emerged as a potential contributor to ALS that is associated with mutations in C9orf72. Recognition that mutations in C9orf72 result in the decreased expression of C9orf72 in people with ALS 8 suggests that the loss of C9orf72 function might contribute to disease. The protein that C9orf72 encodes is a potential guanine exchange factor for one or more as-yet-unidentified G proteins. Its inactivation in mice results in abnormal microglia and age-related neuroinflammation, providing evidence that non-cell-autonomous, microglial-mediated inflammation might contribute to ALS [23] [24] [25] . A crucial contribution of mutant SOD1 to pathogenesis is driven by oligodendrocytes, which are cells that myelinate the axons of upper motor neurons and the initial axonal segments of lower motor neurons. A reduction in the synthesis of mutant SOD1 early in oligodendrocyte maturation produces a more striking delay in the onset of disease 26 than does similar suppression of mutant SOD1 synthesis in motor neurons 16, 19 . Oligodendrocytes also support motor neuron function by directly supplying the energy metabolite lactate to the axon through the action of monocarboxylate transporter 1 (MCT 1) (Fig. 2c) . Mutant SOD1 impairs the expression of MCT 1 by oligodendrocytes in mouse models of ALS 27 . A similar reduction in the accumulation of MCT 1 is found in sporadic ALS 27 , which is consistent with a non-cell-autonomous role for the reduced supply of energy from oligodendrocytes as a general component of ALS pathogenesis.
Another type of glial cell, the astrocyte, provides motor neurons with nutrients, ion buffering and recycling of the neurotransmitter glutamate. The selective reduction of mutant SOD1 synthesis by astrocytes in mice slowed the onset 28 or progression 18 of disease. This delay was accompanied by a delay in the activation of microglia, demonstrating a functional crosstalk between mutant-SOD1-expressing astrocytes and microglia.
One of the earliest proposed mechanisms to underlie ALS was glutamate excitotoxicity, which is the excessive firing of motor neurons that is derived from a failure to rapidly remove synaptic glutamate (Fig. 2d) . Astrocytes limit the firing of motor neurons through the swift recovery of glutamate, a function that is mediated by excitatory amino acid transporter 2 (EAAT2), which transports glutamate into the astrocyte (Fig. 2d) . The loss of EAAT2 has been observed both in SOD1-mutant rodent models of ALS 14, 29 and in samples from people with familial or sporadic ALS 30 . The resulting failure of astrocytes to quickly clear synaptic glutamate triggers the repetitive firing of action potentials and a corresponding increase in calcium influx, as well as endoplasmic reticulum (ER) and mitochondrial stress as the result of overwhelming the calcium storage capacities of these organelles.
Astrocytes also protect motor neurons from excitotoxic damage through the release of an unidentified soluble factor or factors that induce motor neurons to upregulate the glutamate receptor subunit GluR-2 (ref. 31) . The incorporation of GluR-2 into glutamate receptors in neurons reduces the permeability of these receptors to calcium, which provides protection from excitotoxicity by decreasing the influx of calcium. Astrocytes that express mutant SOD1 fail to regulate GluR-2 expression in co-cultured neurons, thereby increasing their vulnerability to excitotoxic damage 31 . Several teams of researchers have used in vitro co-cultures of motor neurons and astrocytes (or astrocyte-conditioned medium) to show that astrocytes expressing ALS-linked mutations produce a toxicity that diffuses to motor neurons [32] [33] [34] [35] [36] (Fig. 2d) . However, there is no consensus on the identity of the toxic species. Notably, astrocytes from people with familial ALS or sporadic ALS (obtained directly from autopsy samples 36 or by isolating neuronal precursor cells that can be converted into astrocytic precursor cells and then astrocytes 35 ) are toxic to co-cultured normal motor neurons. This finding 35 is especially provocative because it indicates that neuronal precursor cells in portions of tissue from people with sporadic ALS have already acquired damage and that this damage is retained following several divisions of these cells in culture and their subsequent differentiation. Whether toxicity from sporadic ALSderived astrocytes is mediated by changes in SOD1 (ref. 35) or not 36 remains unsettled.
Most importantly, a non-cell-autonomous contribution of astrocytes to ALS-like disease has been demonstrated in rodents expressing mutant SOD1 in which transplantation to the spinal cord of lineagerestricted astrocyte precursors without SOD1 mutations delayed progression of the disease 37 .
ALS genes induce ER stress or impair protein degradation ER stress has been implicated broadly in ALS (Fig. 2a) . Initial evidence arose from studies of mutant SOD1 in which misfolded SOD1 binds to the cytoplasmic surface of the ER integral membrane protein derlin-1 (ref. 38) . This binding leads to the inhibition of ER-associated degradation (ERAD), the pathway for extraction and degradation of misfolded proteins from the ER. Moreover, relieving ER stress delays the progression of disease in an animal model of ALS 39 .
There is now overwhelming evidence to show that disruption of the Careful observation of people with ALS over the past 30 years has revealed clinical, pathological and genetic overlap with several other neurodegenerative disorders. In particular, the loss of motor neurons may be accompanied by the loss of cortical neurons in the frontal and temporal cortices of the brain. This correlates clinically with FTD, a condition of impaired judgment and executive skills, which often leads to behavioural disturbances. About 20% of people with ALS meet the clinical criteria for a concomitant diagnosis of FTD, although as many as 50% of people with ALS experience cognitive impairment. Less frequently, ALS occurs together with Paget's disease of bone (PDB) or inclusion body myopathy (IBM). Similar to ALS, both FTD and IBM are characterized by inclusions of TDP-43 and related RNA-binding proteins. The relationship between ALS, FTD, PDB and IBM has been extended though genetic evidence, which potentially places them in the continuum of a broader degenerative disorder. REVIEW INSIGHT two main protein clearance pathways, the ubiquitin-proteasome system and autophagy, can be central components of the disease mechanism in ALS (Fig. 2a) . Several ALS-causing mutations occur in genes with products that are involved directly in protein degradation, including ubiquilin-2 (ref. 40 ) and sequestosome-1 (ref. 41) , both of which function as adapters that bring polyubiquitinated proteins to the proteasome or the autophagosome for degradation. Mutations have also been reported in optineurin 42 , a proposed receptor for autophagy 43 , and valosin-containing protein (VCP) 44 , which has a role in ERAD and sorting endosomal proteins. Other studies have reported FTD-linked mutations in CHMP2B 45 , which encodes a protein that has been implicated in maturation of the autophagosome and endosomal cargo sorting and degradation. ALS-linked mutations are also found in VAPB 46 , the product of which functions in the unfolded protein response in the delivery of ER-ejected substrates to the proteasome. A preponderance of biochemical evidence has demonstrated a decrease in the activities of the proteasome in lumbar spinal cords before symptoms occur in mice that express mutant SOD1 (ref. 47) or following the sustained expression of mutant SOD1 in a cultured line of neurons 48 .
Axonal disorganization and disrupted transport in ALS
Disorganization of the axonal cytoskeleton, and especially of the neurofilaments, is a conspicuous feature both of familial ALS and sporadic ALS (Fig. 2e) . As the most asymmetric cells in nature, and with axons that can reach more than 1 metre in length, motor neurons must rely on axonal transport to deliver components that are synthesized in the cell bodies to axons and synapses. ALS-linked mutant SOD1 has been demonstrated to slow both anterograde 49 and retrograde 50,51 transport routes months before neurodegeneration. Indeed, reduction in retrograde transport through mutations in dynactin 52 , which is an activator of the retrograde motor cytoplasmic dynein 53 , provokes motor neuron disease in humans. Owing to the peculiar architecture of neurons, it is a challenge for these cells to alter local gene expression at the synapse in response to neuronal input or changes in the synaptic environment. To achieve this, neurons must transport all necessary components for translation (for example, messenger RNA, ribosomes and translation factors) to distal sites for local protein synthesis 54 . The spatial distribution of mRNAs depends on the proper microtubule-dependent transport of neuronal RNA transport granules and other factors, and it is regulated by several RNA-binding proteins that are associated with ALS, including TDP-43, FUS and heterogeneous nuclear ribonucleoprotein (hnRNP) A1. ALS-causing mutations in TDP-43 impair the axonal transport of RNA granules in Drosophila and in cultured neurons, including motor neurons derived from people with ALS 55 .
A prion-like spread in inherited ALS
. Prion-like propagation and development of disease that is initiated focally has been shown to occur after the injection of lysates containing mutant SOD1 into mice that express mutant SOD1 (ref. 60 ). This finding replicates the correlation between focal initiation and spreading in people with familial ALS or sporadic ALS 61 . That said, prion-like propagation of SOD1 (or other ALS-linked proteins) has not been achieved in rodents without the coexistance of a pre-existing, weakly active mutant ALS gene. It is unresolved whether this evidence challenges the prion-like spread model of sporadic ALS or, alternatively, whether it raises the possibility that there must be a pre-existing sensitivity in individuals who develop sporadic ALS that facilitates such spreading. Coupled with the recognition that misfolded mutant SOD1 can be secreted by motor neurons or astrocytes 62 , potentially through the newly discovered pathway in which misfolded proteins are secreted unconventionally as an adaptation to proteasome dysfunction 63 , stochastic focal initiation provides a plausible mechanism for the age-dependent onset of disease and its subsequent spread. As most cases of ALS are marked by aggregated TDP-43 rather than SOD1, an unresolved question is whether TDP-43 also exhibits templated misfolding that can spread from cell to cell. . TDP-43 mislocalization is now recognized widely as the hallmark of both sporadic ALS and most familial forms of ALS. This seminal discovery has implications beyond ALS because TDP-43 mislocalization to cytoplasmic inclusions is also the hallmark of FTD that lacks tau-containing inclusions (about half of all cases of FTD) and inclusion body myopathy (IBM) 7, 64 , which are diseases that show genetic overlap with ALS. Moreover, TDP-43 pathology is also found as a secondary pathological feature in a subset of people with Alzheimer's disease or Parkinson's disease 65, 66 . The importance of TDP-43 in pathogenesis was cemented by the identification of ALS-causing mutations in this protein 67 . The subsequent identification of ALScausing mutations in related proteins that bind RNA, including FUS and hnRNP A1, focused substantial attention on the role of RNA biology in ALS pathogenesis [68] [69] [70] [71] (Fig. 2f) . TDP-43, FUS and hnRNP A1 are members of the hnRNP family of proteins that regulates RNA metabolism at every stage of the RNA life cycle. They bind to thousands of RNA targets [72] [73] [74] [75] , which means that a disturbance in the function of one or more of these proteins has the potential to affect RNA metabolism on a broad scale. Phase separation gives rise to membraneless organelles RNA metabolism occurs in complex RNA-protein assemblies that can coalesce into a variety of membraneless organelles such as nucleoli and stress granules. Interestingly, these organelles behave as complex liquids that arise through phase separation, a process in which protein-laden RNAs separate from the surrounding aqueous nucleoplasm or cytoplasm in a manner that is akin to the separation of oil from vinegar 78 . Phase separation is mediated by low-complexity domains that are present in RNA-binding proteins such as TDP-43, FUS and hnRNP A1 (refs 79-81) (Fig. 3a, b) . The assembly of membraneless organelles is a strategy of cellular compartmentalization that governs many biological processes. However, the contribution of phase transition to this process presents a risk because RNA-binding proteins with low-complexity domains, which are prone to fibrillization, are placed in close proximity. Indeed, mutations that cause ALS are found frequently in the low-complexity domains of TDP-43 (ref. 82) , FUS 83 and hnRNP A1 (ref. 70) . As a consequence, these mutations alter the dynamics of membraneless organelles and also accelerate fibrillization, which results in the formation of amyloid-like fibrils that are deposited in the cell bodies and the neuropil [79] [80] [81] 84 (Fig. 3c) . Mutations in the low-complexity domains of at least six different hnRNPs result in a clinico-pathological spectrum that ranges from ALS and FTD to IBM (Fig. 3a and Box 1) . Notably, some disease-causing mutations in RNA-binding proteins do not affect low-complexity domains. For example, several ALS-causing mutations in FUS and hnRNP A1 disturb the nuclear localization sequence of these proteins and result in their accumulation in the cytoplasm 68, 69, 71 . Phase transition by RNA-binding proteins that contain low-complexity domains is exquisitely dependent on concentration 79 , and it is probable that the increased accumulation of FUS and hnRNP A1 in the cytoplasm as a consequence of mutations that affect the nuclear localization signals of these proteins is sufficient to drive excess phase separation, as shown by the hyperassembly of stress granules in cells derived from people with relevant mutations 70, 85 .
RNA metabolism defects in ALS
Disturbance of the normal phase transitions carried out by RNA-binding proteins can have deleterious consequences, including altering the material properties of RNA granules and impairing their function 55 . Moreover, persistent assembly of RNA-binding proteins in the highly concentrated liquid state may promote the formation of amyloid-like fibrils that have toxic properties 79, 80 and may also result in a partial or complete loss of the normal function of important RNA-binding proteins 86 . A well known feature of ALS histopathology is the redistribution of TDP-43 from the . A similar redistribution is observed for FUS and hnRNP A1 when disease-causing mutations occur in the genes that encode these proteins 68, 69, 71 . This redistribution of proteins might reflect a cytoplasmic sink that is produced by the hyperassembly of cytoplasmic granules or by poorly dynamic RNA granules that fail to disassemble appropriately, the deposition of amyloid-like fibrils and defects in nucleocytoplasmic trafficking, as well as other potential mechanisms.
The culmination of this redistribution is the depletion of RNA-binding proteins in the nucleus that has the potential to cause a considerable loss of nuclear function. A well known function of TDP-43 in the nucleus is the regulation of alternative splicing 87 . Experimental depletion of TDP-43 in rodents was found to alter hundreds of splicing events in the brain, resulting in the depletion of several RNAs that encode synaptic proteins 73 . The loss of nuclear TDP-43 also facilitates the use of cryptic splice sites 88 that, in general, might lower the levels of correctly spliced protein-encoding mRNAs. Furthermore, TDP-43 autoregulates its synthesis 73 , which establishes the possibility of a feed-forward mechanism that amplifies the impact of the partial loss of TDP-43 function.
The loss of FUS or hnRNP A1 from the adult nervous system produces defects analogous to those associated with the loss of TDP-43, although different subsets of mRNAs are linked to the depletion of each of these RNA-binding proteins 74, 75 . An important, unanswered question concerns the extent to which ALS caused by other genetic perturbations, especially C9orf72-related ALS, also involves disturbances in RNA biology that intersect mechanistically with mutations in TDP-43, FUS and hnRNP A1.
The biogenesis of regulatory RNA and its function in ALS
Both TDP-43 and FUS are components of macromolecular complexes that generate small non-coding RNAs known as microRNAs (miRNAs) with functions in RNA silencing. The loss of TDP-43 or FUS results in a reduction in the expression of miRNAs in model systems, including Drosophila models and induced pluripotent stem (iPS)-derived motor neurons from people with TDP-43 mutations, which suggests a possible role for altered RNA silencing in ALS 89 . Various miRNAs contribute to the maintenance of neuromuscular junctions, implying that motor neurons might be particularly sensitive to disturbances in the biogenesis of miRNA 90, 91 . Indeed, global downregulation of miRNAs has been reported in motor neurons from people with sporadic ALS 92 , although the role of reduced levels of miRNAs in the pathogenesis of ALS remains to be established 92 . Nonetheless, the expression of regulatory RNAs seems to be altered robustly and consistently in the serum of people with ALS, and this could present an opportunity for the development of biomarkers 93 .
The curious case of C9orf72-related ALS and FTD
Although the identification of ALS-causing mutations that affect SOD1 and RNA-binding proteins highlighted pathophysiological pathways through which disease might arise, most of the genetic burden of ALS remained unaccounted for until 2011. Genetic linkage studies 94, 95 followed by several large genome-wide association studies [96] [97] [98] [99] identified the location of a gene in the chromosome 9p21 locus in which mutations cause both ALS and FTD. During sequencing of the non-coding regions of candidate genes in chromosome 9p21, a pathogenic expansion of a hexanucleotide repeat in C9orf72 was identified as the basis for C9orf72-related ALS and FTD (C9 ALS-FTD) 8 . In healthy individuals, the sequence GGGGCC was present as 2-23 repeats but in affected individuals it was expanded to hundreds or thousands of repeats. In parallel, an independent study also discovered a pathogenic expansion of GGGGCC repeats in C9orf72 (ref. 77 ).
The consequences of repeat expansion in C9orf72
Three non-exclusive mechanisms have been proposed through which expanded GGGGCC repeats might cause C9 ALS-FTD (Fig. 4) . First, a reduction in the expression levels of C9orf72 in people with C9 ALS-FTD 100 has led to speculation that the loss of C9orf72 protein may contribute to disease. The function of C9orf72 is poorly understood; however, the protein is known to contain a conserved DENN domain and can function as a guanine-nucleotide exchange factor for several Rab proteins in experimental systems 101 . In cultured cells and in zebrafish, the depletion of endogenous C9orf72 can exacerbate the toxicity of aggregation-prone proteins such as polyglutamine-expanded ataxin-2 (ref. 102) . However, the reduction of endogenous C9orf72 mRNA with antisense oligonucleotides was well tolerated in mice and did not result in impairments to behaviour or motor functions 103 . Furthermore, the conditional knockout of the gene C9orf72 in the brains of mice did not cause noticeable motor neuron or other neurodegenerative phenotypes, and there was no evidence of the hallmark pathological features of ALS or FTD 104 . Mice in which there was a complete ablation of C9orf72 in all tissues developed and aged normally without the occurrence of motor neuron disease; however, they also developed progressive splenomegaly , hnRNP DL and TIA-1) harbouring mutations that produce a spectrum of disease that ranges from ALS or FTD to myopathy. LCD, low-complexity domain; MSP, multisystem proteinopathy; NLS, nuclear localization signal; RRM, RNA recognition motif. b, RNAbinding proteins that contain a low-complexity domain can undergo phase separation, which is the transition from a single, mixed phase (top) to two distinct phases (bottom), one of which is a concentrated liquid droplet (green). c, Phase separation contributes to the assembly, dynamics and liquid properties of membraneless organelles; however, the high concentration and close positioning of the low-complexity domains risks the transitioning of such proteins (for example, TDP-43) to pathological, amyloid-like fibrils. RBP, RNAbinding protein; RNP, ribonucleoprotein. Two phases
Deposition of amyloid-like brils and lymphadenopathy [23] [24] [25] 105 . These mice were found to have abnormal macrophages and microglia, as well as age-related neuroinflammation 23, 105 and signs of autoimmunity 25 , which raises the possibility of a non-cellautonomous inflammatory contribution to C9 ALS-FTD.
Nevertheless, the dominant inheritance pattern of C9 ALS-FTD, the absence of people with ALS or FTD with null alleles or missense mutations in C9orf72 and the absence of neurodegeneration in C9orf72-knockout mice provide arguments against the loss of C9orf72 function as the sole driver of disease. Indeed, most empirical evidence points to the gain of toxic functions as the main mechanisms that drive neurodegeneration in C9 ALS-FTD. For example, the adeno-associated virus-mediated delivery to the brain of a construct that expresses expanded GGGGCC repeats elicits neurodegeneration 106 , although the nature of the toxic species in C9 ALS-FTD remains unclear.
Gain of toxic function from repeat-containing RNA
The initial description of the mutation in C9orf72 was accompanied by evidence to show that RNA foci containing the GGGGCC repeat accumulate in the brains and spinal cords of people with C9 ALS-FTD 8 (Fig. 1b) , and this suggested a second possible disease mechanism, involving toxic gain of function by repeat-containing RNA (Fig. 4) . It was then noted that the gene C9orf72 can be transcribed bidirectionally and that foci containing sense (GGGGCC) or antisense (CCCCGG) RNA transcripts accumulate in affected cells [107] [108] [109] . The accrual of such foci in C9 ALS-FTD is reminiscent of the pathological RNA foci that are observed in myotonic dystrophy type 1, myotonic dystrophy type 2 and fragile X-associated tremor and ataxia syndrome, which are also caused by the expansion of nucleotide repeats in non-coding regions 110 . In these diseases, the accumulated repeat-containing RNA sequesters RNA-binding proteins that are involved in splicing, which leads to defects in splicing that underlie some aspects of pathogenesis 110 . Similarly, a number of RNA-binding proteins bind to expanded GGGGCC or GGCCCC repeats in vitro, and a rare co-localization with RNA foci has been observed for several of these proteins in tissue from affected individuals [111] [112] [113] [114] [115] . Simple model systems have illustrated the functional consequences of the sequestration of some hexanucleotide repeat-binding proteins, including transcriptional activator protein Pur-α and Ran GTPaseactivating protein 1 (RanGAP1), but the contribution of these interactions to the development of disease is not yet established 114, 116 . Notably, repeats of GGGGCC (but not of CCCCGG) can adopt a stable secondary structure known as a G-quadruplex, which might contribute to the persistence of this species of RNA as well as to its ability to reach distal neurites and associate with RNA-binding proteins in transport granules and potentially interfere with local translation [117] [118] [119] .
Gain of toxic function from dipeptide repeats
Substantial evidence has also accrued to implicate a third disease mechanism in C9 ALS-FTD; specifically, toxicity from DPR proteins that are produced by repeat-associated non-AUG (RAN) translation (Fig. 4) . This unconventional type of translation occurs in the absence of an initiating AUG codon and might rely on secondary structures formed by repeat-expanded RNA 120 . In C9 ALS-FTD, RAN translation occurs in all reading frames and from both sense and antisense transcripts, and it results in the production of five DPR proteins: glycine-alanine (GA) and glycine-arginine (GR) from sense GGGGCC transcripts; proline-arginine (PR) and proline-alanine (PA) from antisense GGCCCC transcripts; and glycine-proline (GP) from both sense and antisense transcripts [107] [108] [109] . All of these DPR proteins are produced in people with C9 ALS-FTD and they account for the neuronal cytoplasmic and intranuclear inclusions that contain ubiquitin and sequestosome-1 but lack TDP-43 that are found widely in the brain and spinal cord 107, 109, 113, 121, 122 (Fig. 1b) . The timing, location and level of expression of each species of DPR protein in the brains of affected people are yet to be clarified. Several reports have described the deposition of DPR proteins in the brains of people with C9 ALS-FTD, and in some instances an inverse relationship has been described between the regional burden of DPR proteins and the corresponding severity of neurodegeneration 123, 124 . These studies were based on the post-mortem examination of brains with end-stage disease and relied on the detection of large inclusions using immunohistochemistry, an approach that probably under-represents the pathological burden of soluble DPR proteins. However, the apparent discrepancy between the burden of DPR-protein deposition, the levels of which are greatest in the cerebellum, and the severity of neurodegeneration, which is greatest in the motor cortex and spinal cord, needs to be resolved to understand the role of DPR proteins in the development of disease.
Some species of DPR proteins have been shown to be toxic in cultured cells and animal models of disease, although high levels of expression were sometimes used to produce short-term toxicity. The arginine-containing DPR proteins GR and PR seem to be most toxic. For example, when GR or PR is added to cells in culture, it enters and accumulates in nucleoli, which leads to defects in RNA processing and subsequent cell death 125 . Similarly, the independent expression of each of the five species of DPR proteins in cultured neurons revealed that GR and PR are very toxic, whereas PA, GA and GP are well tolerated. Observations in Drosophila engineered to express each of the five DPR proteins have also shown that GR and PR are extremely toxic to neuronal tissue, whereas GA is modestly toxic and GP and PA seems to be non-toxic [126] [127] [128] . A recent discovery is that the arginine-containing DPR proteins GR and PR bind to proteins that contain low-complexity domains 129, 130 . Furthermore, GR and PR alter the phase separation of such proteins, resulting in the perturbed assembly, dynamics and function of membraneless organelles such as stress granules and nucleoli 129 . This finding mirrors the defects in phase transitions that are observed with disease-causing mutations in the low-complexity domains of TDP-43, FUS and hnRNP1, suggesting a common pathological mechanism.
However, other investigations have reported that toxicity is associated with the expression of GA in cell culture [131] [132] [133] and its adeno-associated virus-mediated delivery to the mouse brain 133 . It should be noted that these efforts to model the toxicity of DPR proteins have used short (fewer than 100) repeats. How the properties of those short DPR proteins compare with the possibly larger products of RAN translation in affected individuals is also unknown.
A defect in nucleocytoplasmic trafficking
Whereas the nature of the gain of toxic function is still an open question, in C9orf72 from fewer than 23 copies to hundreds or thousands of copies causes C9 ALS-FTD. This mutation results in a modest reduction in the levels of C9orf72 protein (left) that seems insufficient to cause disease but might contribute to its progression through abnormal microglial responses. Meanwhile, the expression of sense and antisense RNA transcripts that contain the expanded repeat probably drive a toxic gain of function (right). The two main gain-of-function modes that are implicated are: toxicity through the sequestration of RNA-binding proteins in RNA foci by the expanded GGGGCC repeat RNA transcript; and the production of DPR proteins through RAN translation, leading to toxicity through several cellular targets such as membraneless organelles and nuclear pores. 
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converging evidence suggests that impaired nucleocytoplasmic trafficking is one of the downstream consequences of mutations in C9orf72.
A comprehensive, unbiased screen in Drosophila for genetic modifiers of the toxicity that is mediated by expanded GGGGCC repeats identified 18 genes that are connected to the nuclear pore complex and nucleocytoplasmic trafficking 128 . A separate unbiased screen for genetic modifiers of PR toxicity in yeast also identified numerous genes that encode components of the nuclear pore complex and effectors of nucleocytoplasmic trafficking 134 . A third study focused on the nucleocytoplasmic transport factor RanGAP1, which binds to the RNA sequence GGGGCC. Genes encoding RanGAP1 and other nucleocytoplasmic transport factors were identified as modifiers of toxicity mediated by expanded GGGGCC repeats in Drosophila
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. Consistent with these results, morphological abnormalities were found in the nuclear envelope architecture in both cell-based and animal models of disease, as well as in the brains of people with C9 ALS-FTD. Moreover, defects in the nucleocytoplasmic transport of RNA and proteins were found in neurons derived from the iPS cells of people with C9 ALS-FTD 116, 128, 134 .
Approaches to therapy for C9 ALS-FTD
The relative contributions of the various proposed modes of toxicity to the development of C9 ALS-FTD is an important consideration that will influence strategies for therapeutic intervention. Efforts are underway to impede RAN translation with small molecules but the success of such an approach will depend on the role of DPR proteins in disease. Irrespective of the main basis for the toxic gain of function, the mutant gene C9orf72 presents an attractive target for therapeutic intervention. For example, antisense oligonucleotides are able to reverse pathological features in neurons derived from iPS cells 103, 135, 136 or in fibroblasts 103 from people with C9 ALS-FTD. Indeed, neurons and glial cells derived from iPS cells might prove to be a useful model system in which to develop approaches for mitigating toxicity related to mutant C9orf72 even before the basis of toxicity has been elucidated fully. Therapeutic efforts will be aided further by the development of transgenic mouse models that express human C9orf72 that contain about 450 hexanucleotide repeats, which recapitulate aspects of the molecular pathology 24, [137] [138] [139] , neuropsychological deficits 24, 139 and the motor phenotype 139 of C9 ALS-FTD. It is also particularly promising that pathological abnormalities can be reversed, and that the development of neuropsychological deficits can be delayed, by a single-dose infusion of an antisense oligonucleotide that induces the catalytic degradation of hexanucleotide-containing RNAs without exacerbating a reduction in RNAs encoding the C9orf72 protein 24 .
Looking forward
Clearly, there has been dramatic progress towards defining the genetic topography and molecular biology of ALS. There is also little doubt that the pace of discovery will continue or even accelerate in several areas of research.
First, it is certain that our understanding of the genetic basis of ALS will continue to evolve. Research programmes are already in place to collect and sequence thousands of whole genomes from people with ALS. More genes that are implicated in ALS are likely to be defined, both through conventional Mendelian genetics and through enhanced association studies that identify increased burdens of rare genetic variants, including those found in non-coding DNA. In parallel, enhanced scoring and recording of quantifiable clinical parameters will permit the definition of variants that modify the phenotype of ALS. The existence of extensive ALS genome databases will enable the first comprehensive studies of epistasis, characterizing the interactions of numerous genes to perturb the viability of motor neurons.
Second, although the past two decades have witnessed extraordinary progress in understanding familial ALS, it is probable that insights that help to elucidate sporadic ALS will be acquired. One view is that all cases of sporadic ALS will ultimately be shown to reflect several genetic determinants. Alternatively, there is increasing interest in exogenous factors that might trigger sporadic neurodegeneration, and atypical infections or the activation of endogenous retroviruses 140 are proposed to have such a role. Although the role of external environmental factors in ALS has been elusive, there is fresh interest in the influence of the intrinsic environment, represented by the microbiome, on development of the disease.
Last, and perhaps most importantly, there will be considerable achievements in the development of therapies for ALS. Although daunting, the complexity of the molecular pathology of ALS is promising as a roadmap for defining therapeutic targets. Moreover, for types of ALS that arise from well-defined genetic defects, advances in gene silencing and gene editing technologies will permit personalized therapeutic programmes. When combined with improved methods for the delivery of therapies to the central nervous system, these approaches will lead to strategies for attenuating the lethal course of ALS. ■
